
|Videos|January 22, 2014
The Future of Bladder Cancer
Author(s)Arjun Balar, MD
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
Advertisement
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
Clinical Pearls:
- Within the next 10 years, physicians will have hopefully moved away from using chemotherapy to treat patients with bladder cancer
- Physicians need to refine their understanding of the genetic makeup of bladder cancer in order identify validating predictive biomarkers
- Hopefully in the future, physicians will be able to biopsy a tumor in real time, identify actionable alterations in the patient’s tumor, and select a particular therapy based on the findings
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































